Sends response and compliance report for observation for both facilities
Natco Pharma updated that an inspection was conducted by the United States Food & Drug Administration (USFDA) in two of its manufacturing facilities recently, the Active Pharmaceutical Ingredients (API) manufacturing facility at Manali, near Chennai, and the Pharmaceutical Formulations facility at Kothur, near Hyderabad, during early February and March, 2016, respectively.The company has received 483 observations for both facilities and believes them to be of minor in nature. The company has already sent response and compliance report for these observations and believes that there would be no adverse impact to its current or future pipeline products coming from these facilities.
Powered by Capital Market - Live News
